Contigen

PreclinicalSmall molecule

SStanford University

Contigen is one of 4 small molecule programs targeting Stress urinary incontinence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stress Urinary IncontinenceActive, not recruiting

Stress Urinary IncontinencePreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Stress Urinary Incontinence

#DrugCompanyPhaseTrials

Activella

Eli Lilly

Preclinical

1 2

Andriol

AAuxilium

Preclinical

1 3

Propiverine Hydrochloride

LLee's Pharmaceutical Limited

Preclinical

1 4

Contigen

SStanford University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stress urinary incontinence1 trial

Male Stress Urinary Incontinence and Sexual Health

Withdrawn·SStanford University··NCT01379378

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Contigen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Contigen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Contigen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

Contigen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stress urinary incontinence1 trial

References

Drug Info

Quick Facts

Related News